JOYCE HENRY-HAEDRICH: Open Payments
NPI 1235801960 · REDDING, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$721 in 28 payments from 18 companies in 2025. Trend: 2023 $319 · 2024 $258 · 2025 $721
Food & beverage: $721
| Company | Payments | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $116 |
| Biogen, Inc. | 3 | $71 |
| Otsuka America Pharmaceutical, Inc. | 2 | $59 |
| ABBVIE INC. | 2 | $52 |
| Alexion Pharmaceuticals, Inc. | 2 | $51 |
| UCB, Inc. | 2 | $44 |
| PFIZER INC. | 2 | $42 |
| Neurocrine BioSciences, Inc. | 1 | $35 |
| Merz Pharmaceuticals, LLC | 1 | $33 |
| Eisai Inc. | 1 | $31 |
Products named: HYQVIA, REXULTI, ULTOMIRIS, TYSABRI, NURTEC ODT, INGREZZA, Xeomin, Leqembi.
Industry payments across CA — which companies pay providers there.
